



Press Release – St. Joseph, Michigan, USA and Basel, Switzerland, February 13th 2006

GeneGo and Genedata Combine Forces to Produce Ultimate Enterprise Platform

GeneGo Inc. and Genedata AG, providers of computational solutions for systems biology and biomarker discovery, announce that their computational systems have successfully been integrated to support a seamless data analysis workflow. The workflow supports target selection and validation as well as diagnostic and biomarker applications.

"Today, drug discovery scientists handle very complex "genome wide" experimental datasets. To cope with such complexity they need a variety of analytical approaches and databases not available from any single source. Therefore, cooperation between computational biology specialists is logical and beneficial for end users", explained Julie Bryant, Vice President of Business Development at GeneGo Inc.

GeneGo's flagship analytical suite, MetaCore™ combines a manually curated database of clinical and pre-clinical biology information and bioactive compounds with comprehensive pathways and network analyses. Bryant added, "MetaCore can now be connected with Genedata Expressionist® and Genedata Phylosopher®, so mutual customers will be able to move iteratively between the software systems seamlessly and inter-operatively".

"Genedata's open and scalable architecture provides a strong basis for integration with client and third party content", says Dr. Daniel Keesman, CEO of Genedata AG. Expressionist enables omics data and associated information to be imported, processed and analyzed in an automated and repeatable workflow. Phylosopher has been integrated closely with MetaCore's visualization tools to identify and prioritize pathways affected by disease. The integrated solution achieves unrivaled standards in research information management and decision support. Dr. Keesman added, "This integration has been customer-led and helps scientists place their results in biological context, thus deriving maximum benefit from experimental data".

Contact

Genedata AG
Dr. Tobe Freeman
Manager Public Relations
Phone +41 61 697 8510
Fax +41 61 697 7244

tobe.freeman@genedata.com

www.genedata.com

GeneGo Inc.
Julie Bryant
VP Business Development & Marketing
Phone +1 858 756 7996
Fax +1 858 756 9446

julie@genego.com

www.genego.com

Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data. Genedata Screener® for high throughput screening analysis. And Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Munich (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Japan, Taiwan and Singapore. For more information about Genedata, please visit: www.genedata.com.

GeneGo (www.genego.com) develops tools for integration and systems level analysis of high-throughput experimental data in human biology and medicinal chemistry. The MetaCore platform is a manually curated, proprietary database for systems biology. It includes genes, proteins, compounds, metabolites, ligands, transcriptional factors and hormones for human, mouse, rat, dog, chicken, chimpanzee, worm, fly and yeast. Researchers can overlay gene expression, proteomic, metabolomic, SNP and SAGE data in the context of pathways. GeneGo is developing workflows for customers using Pipeline Pilot. MetaDrug is a systems ADME/Tox platform that has been integrated with Pipeline Pilot allowing researchers to develop workflows to bring in lists of compounds, predict metabolites, prioritize them and then visualize the important metabolites in pathways to ensure that compounds that move forward have the greatest opportunity for success.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.